When the First Treatment for Depression Doesn’t Work
When the first treatment you try for your depression doesn’t work, it can feel utterly painful. As it is, depression makes you feel hopeless and helpless. An ineffective intervention might feel like the final straw.
But it’s actually not uncommon for the first treatment to be unsuccessful. In fact, about 40 to 50 percent of people don’t respond to the first antidepressant they’re prescribed, according to Jonathan E. Alpert, M.D., Ph.D, the associate director of the Massachusetts General Hospital Depression Clinical and Research Program and co-founder and co-director of the Depression and Anxiety Group Practice.
Sti...
Source: Psych Central - April 20, 2013 Category: Psychiatry Authors: Margarita Tartakovsky, M.S. Tags: Depression Disorders General Medications Self-Help Treatment Antidepressant Bipolar Disorder Co Director Depression And Anxiety Depression Anxiety Depression Treatment Final Straw Group Practice Hyland Hypothyroidism Incorr Source Type: news
Stop-Smoking Drugs Not Equal in Real Life (CME/CE)
(MedPage Today) -- Varenicline (Chantix) may hold some longer-term advantages for smoking cessation compared with bupropion (Zyban, others), according to a community-based trial. (Source: MedPage Today Psychiatry)
Source: MedPage Today Psychiatry - March 28, 2013 Category: Psychiatry Source Type: news
Choosing a Generic AntidepressantChoosing a Generic Antidepressant
With one generic bupropion formulation recently withdrawn, how can clinicians best select from among the remaining options? FDA on Medscape (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - February 4, 2013 Category: Consumer Health News Tags: Psychiatry Expert Interview Source Type: news
Antidepressant link to heart changes confirmed
Conclusion
This study shows a link between three antidepressants (two SSRIs and one tricyclic) and prolonged QT interval (a risk factor for rare but serious heart rhythm problems). The study did not assess the risk of these heart rhythm problems directly (which is difficult to measure because of their rarity). The researchers point out that the recent FDA warning over the risks of citalopram was based on its association with prolonged QT interval only, and “in spite of the epidemiological data showing no difference in risk for arrhythmia [heart rhythm abnormality]”.
The researchers say that certain SSRIs were not signi...
Source: NHS News Feed - January 31, 2013 Category: Consumer Health News Tags: Medication Mental health Source Type: news
Families face battle with GSK over dangerous diabetes drug
Exclusive: Pharmaceutical giant resists claims despite settlement with victims in USThousands of families in the UK could be deprived of compensation for the death or harm of a relative caused by the diabetes drug Avandia, even though the British maker has agreed to pay billions of dollars to settle similar claims in the US.The licence for Avandia was revoked in Europe, in September 2010, because of evidence that it could cause heart failure and heart attacks. The drug can still be prescribed in the US, but not to patients at risk of heart problems.A scientist with the Food and Drug Administration estimated that Avandia co...
Source: Guardian Unlimited Science - January 29, 2013 Category: Science Authors: Sarah Boseley Tags: The Guardian United States World news Pharmaceuticals industry Medical research Legal aid Law UK news Diabetes GlaxoSmithKline Business Source Type: news
Smoking-Cessation Drug Not Effective in the Post-AMI SettingSmoking-Cessation Drug Not Effective in the Post-AMI Setting
Although safe and well tolerated in the immediate post-AMI period, treatment with bupropion failed to halt cigarette smoking, as more than two-thirds returned to smoking by 12 months after their AMI. Heartwire (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - January 29, 2013 Category: Consumer Health News Tags: Cardiology News Source Type: news
Smoking-cessation drug bupropion not effective in the post-AMI setting
Although safe and well tolerated in the immediate post-AMI period, treatment with bupropion failed to halt cigarette smoking, as more than two-thirds returned to smoking by 12 months after their AMI. (Source: theHeart.org)
Source: theHeart.org - January 28, 2013 Category: Cardiology Source Type: news
Stop-Smoking Drug No Help After MI (CME/CE)
(MedPage Today) -- Taking bupropion (Zyban) right after a heart attack won't help smokers quit, researchers found. (Source: MedPage Today Cardiovascular)
Source: MedPage Today Cardiovascular - January 28, 2013 Category: Cardiology Source Type: news
Bupropion Med Profile
Bupropion is an antidepressant, also sold as Zyban to help people quit smoking. The brand name of the antidepressant form is Wellbutrin. Here are important facts about bupropion HCl. (Source: About.com Bipolar Disorder)
Source: About.com Bipolar Disorder - January 10, 2013 Category: Psychiatry Authors: bipolar.guide at about.com Tags: health Source Type: news
Taking Bupropion, Wellbutrin or Zyban? Facts You Need
Here are important things you should know if you're taking one of these three drugs in any form. For example, people with a history of anorexia or bulimia shouldn't take ...Read Full Post (Source: About.com Bipolar Disorder)
Source: About.com Bipolar Disorder - January 6, 2013 Category: Psychiatry Source Type: news
FDA Pulls One Generic Form of Wellbutrin Off the Market
Title: FDA Pulls One Generic Form of Wellbutrin Off the MarketCategory: Health NewsCreated: 12/5/2012 6:35:00 PMLast Editorial Review: 12/6/2012 12:00:00 AM (Source: MedicineNet Depression General)
Source: MedicineNet Depression General - December 6, 2012 Category: Psychiatry Source Type: news
